Hsiehchen, David http://orcid.org/0000-0001-9139-302X
Beg, Muhammad S.
Kainthla, Radhika
Lohrey, Jay
Kazmi, Syed M.
Khosama, Leticia
Maxwell, Mary Claire
Kline, Heather
Katz, Courtney http://orcid.org/0009-0007-9323-6766
Hassan, Asim
Kubota, Naoto
Siglinsky, Ellen
Pillai, Anil K.
Youssoufian, Hagop
Mockbee, Colleen
Culm, Kerry
Uhlik, Mark
Benjamin, Laura
Brekken, Rolf A. http://orcid.org/0000-0003-2704-2377
Ahn, Chul
Singal, Amit G. http://orcid.org/0000-0002-1172-3971
Zhu, Hao http://orcid.org/0000-0002-8417-9698
Hoshida, Yujin http://orcid.org/0000-0001-9430-1426
Yopp, Adam C.
Article History
Received: 20 September 2023
Accepted: 1 March 2024
First Online: 11 March 2024
Competing interests
: D.H. has served as a consultant for AztraZeneca. M.S.B. is an employee of Science37. H.Y., C.M., K.C., M.U., and L.B. are employees of OncXerna Therapeutics. A.S. has served as a consultant or on advisory boards for Genentech, AztraZeneca, Eisai, Exelixis, Bayer, Boston Scientific, FujiFilm Medical Sciences, Exact Sciences, Roche, Glycotest, Universal Dx, Freenome, and GRAIL. Y.H. has served as a consultant or on advisory boards for Helio Genomics, Alentis Therapeutics, Espervita Therapeutics, and Roche Diagnostics, and holds shares in Alentis Therapeutics and Espervita Therapeutics. R.A.B. received research support from OncXerna. The remaining authors declare no competing interests.